New drug may help kids with kidney disease avoid relapses
NCT ID NCT07388810
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether one or two doses of ripertamab can help children aged 16 and older who have frequent relapses or steroid-dependent nephrotic syndrome. The goal is to see which dose works better at preventing relapses and reducing the need for steroids. The trial will enroll 312 participants and follow them for one year.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ripertamab
- What this could lead to
- If successful, this could offer a more effective treatment option to reduce relapses and steroid use in children with nephrotic syndrome.
- What could go wrong
- This is an early-stage trial with no phase specified, so results may not confirm benefit. Risks include potential side effects from ripertamab and the steroid regimen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 312 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 16 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. 16 years old and above with FRNS/SDNS 2. Before enrollment, achieved complete remission (urine protein/creatinine ratio (morning urine or 24-hour urine) ≤ 20mg/mmol (0.2mg/mg) or \< 100mg/m2/d, or test strip result negative or trace) 3. Within 2 months before enrollment, did not use levamisole, alkylating agents such as cyclophosphamide, calcineurin inhibitors such as cyclophosphamide and cyclosporine, or mycophenolate mofetil. Within 6 months before enrollment, did not use other CD20 monoclonal antibodies (such as ofatumumab, otuzumab, etc., excluding rituximab) 4. Glomerular filtration rate (eGFR) \> 60ml/min/1.73m2 5. The patient or their guardian agrees to participate in this clinical trial and signs the informed consent form, indicating that they understand the purpose and procedures of this clinical trial and are willing to participate in the study Exclusion Criteria: 1. Known causes (such as systemic lupus erythematosus, IgA nephropathy, other secondary nephrotic syndromes, amyloidosis, malignant tumors, etc.) 2. Known active chronic infections, including tuberculosis, HIV, HBV, HCV, etc. 3. Severe leukopenia (white blood cells \< 3.0×109/L), severe anemia (hemoglobin \< 8.9 g/dl), thrombocytopenia (platelets \< 100×109/L), or liver dysfunction (alanine aminotransferase/aspartate aminotransferase \> 2 times the upper limit of normal) 4. Received live vaccines within 1 month prior to screening 5. Currently participating in other drug clinical trials 6. Other conditions that the investigator deems make the patient unsuitable for this study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRNS/SDNS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province 310052
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.